[Aju News] [Legal Update] “Stop Technology Theft”… Quintuple Punitive Damages Allowed for Trade Secret Misappropriation
On February 13, 2024, Aju News shared in its news article Lee & Ko’s attorney Mr. Un Ho Kim’s remark on a recent update regarding the Act on the Prevention of Unfair Competition and Protection of Trade Secrets. Mr. Kim explained that, with proposed amendments to the Act now passed at the Cabinet meeting, “businesses should be mindful that damages awarded in intellectual property cases could increase significantly and so is the possibility of criminal punishment, and should establish meticulous measures to prevent infringement of intellectual property rights.” He further commented, “in the event of an intellectual property dispute, the right holder needs to actively utilize the relevant provisions in the Act.”
2024.02.13
[Forbes] [ANNUAL BRIEF 2004] Interview | Jaewoo Kwak, Partner, Lee & Ko
Forbes reported an interview with Jaewoo Kwak, a partner of Lee & Ko on January 23, 2024. In the interview, Mr. Kwak, a lawyer specializing in intellectual property rights, stated that although there are currently few cases related to AI worldwide, there will be more in the future. He discussed the intellectual property market for various industries including electronics, materials, chemicals, machinery, automobiles, telecommunications, pharmaceuticals, biotechnology. He also addressed copyright issues related to AI and predicted the trends in laws and regulations governing AI use.
2024.01.23
[Chosun Biz][Law Firm Practice Skills] Lee & Ko Protects Boryung Pharmaceutical’s Right in Hypertension Treatment with KRW 50 Billion in Sales
On January 8, 2024, Chosun Biz reported Lee & Ko’s recent win for Boryung Pharmaceutical, noting that “as the efficacy of Dukarb®, Boryung’s hypertension drug, went viral, it became the target of other Korean pharmaceutical companies” but “Boryung has defended its Dukarb® patent all the way from the Intellectual Property Trial and Appeal Board stage to the ensuing trials, with Lee & Ko’s Healthcare Practice Group, led by Ms. Keum Nang Park, playing a key role in the defense.” Ms. Park remarked in an interview that “this is the first time a Korean pharmaceutical company that has developed an original drug defended its patent rights in a large-scale dispute against multiple generic companies,” further noting that “we felt that this drug should be afforded patent protection especially since it was a new drug developed after many challenges in Korea, where new drug R&D is still rare.”
2024.01.08
[Hankyung] Lee & Ko Prevails in All 10 Lawsuits Relating to Boryung Pharmaceutical’s Ducarb® Patent
On December 5, 2023, Hankyung reported Lee & Ko’s recent win in the lawsuits involving Boryung Pharmaceutical’s combination drug patent related to Ducarb®, Boryung’s blockbuster drug. Representing the patentee, Lee & Ko won in all 10 cases, which included patent invalidation actions and negative scope confirmation actions. Lee & Ko’s team, with attorneys Keum Nang Park, Heon Lee and Eunkyoung Lyu and patent attorneys Tae Min Kim and Sungmin Cho, strategically crafted arguments based on sound and in-depth analysis of legal theories, ultimately securing this victory.
2023.12.05